Intelligence Feed event · Equity · 2026-09-09

    Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance

    Question

    Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance

    Direct answer

    Pfizer delivered stronger-than-projected second-quarter results driven by commercial execution across its non-COVID portfolio. Revenue of $15.0 billion and EPS of $0.77 exceeded consensus estimates of $14.4 billion and $0.68 respectively. Management raised full-year revenue guidance and highlighted pipeline milestones including European Medicines Agency validation for its Lyme disease candidate and recent FDA clearance.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/pfizer-beats-q2-estimates-at-15b-revenue-and-raises-full-year-guidance-7fd51c

    EQUITY
    Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance
    Pfizer delivered stronger-than-projected second-quarter results driven by commercial execution across its non-COVID portfolio. Revenue of $15.0 billion and EPS of $0.77 exceeded consensus estimates of $14.4 billion and $0.68 respectively. Management raised full-year revenue guidance and highlighted pipeline milestones including European Medicines Agency validation for its Lyme disease candidate and recent FDA clearance.
    PFE
    Impact
    70
    SEP 9
    SIG
    88%
    PFE
    Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance
    Pfizer delivered stronger-than-projected second-quarter results driven by commercial execution across its non-COVID portfolio. Revenue of $15.0 billion and EPS of $0.77 exceeded consensus estimates of $14.4 billion and $0.68 respectively. Management raised full-year revenue guidance and highlighted pipeline milestones including European Medicines Agency validation for its Lyme disease candidate and recent FDA clearance.
    → Upward revisions to full-year guidance and regulatory pipeline milestones directly lift PFE forward earnings visibility and dividend coverage confidence.
    Impact
    Pfizer delivered stronger-than-projected second-quarter results driven by commercial execution across its non-COVID portfolio. Revenue of $15.0 billion and EPS of $0.77 exceeded consensus estimates of $14.4 billion and $0.68 respectively. Management raised full-year revenue guidance and highlighted pipeline milestones including European Medicines Agency validation for its Lyme disease candidate and recent FDA clearance.
    Affected
    PFE
    Transmission
    Upward revisions to full-year guidance and regulatory pipeline milestones directly lift PFE forward earnings visibility and dividend coverage confidence.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PFEearnings outperformance and full-year guidance revisionUp1-4wReported Q2 revenue of $15B vs $14.4B expected and raised full-year revenue outlook.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month